Vertex Pharmaceuticals Q3 FY2026 results
$538.60−0.74%
Vertex Pharmaceuticals reported revenue of $3.44 billion, up 11.8% from a year earlier, net income of $654 million and diluted earnings per share of $2.56 against $4.20 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).
From its quarterly report, the results first announced on 2 Nov 2026. Compiled and checked by AapWire.
Q3 FY2026 against Q3 FY2025
Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $3.44B | $3.08B | +11.8% |
| Gross profit | $2.91B | $2.66B | +9.5% |
| Gross margin | 84.7% | 86.5% | −1.8 pts |
| Operating income | $712.9M | $1.19B | −39.9% |
| Operating margin | 20.7% | 38.6% | −17.8 pts |
| Net income | $653.6M | $1.08B | −39.6% |
| Diluted EPS | $2.56 | $4.20 | −39.0% |
| Operating cash flow | $643.1M | $1.24B | −48.2% |
| Capital expenditure | $97.30M | $101.8M | −4.4% |
| Free cash flow | $545.8M | $1.14B | −52.1% |
Operating KPIs for the quarter
| KPI | Q3 FY2026 | Change on a year |
|---|---|---|
| Product revenues, net revenue | $3.4B | up 11.8% |
| TRIKAFTA/KAFTRIO revenue | $2.4B | down 8.2% |
| ALYFTREK revenue | $705.8M | up 185.7% |
| CASGEVY revenue | $99.2M | up 487.0% |
| JOURNAVX revenue | $58.3M | up 197.4% |
| United States revenue | $2.2B | up 9.8% |
| Europe revenue | $1.0B | up 19.8% |
Earlier quarters
| Quarter | Period end | Revenue | Change on a year | Diluted EPS |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sep 2026 | $3.44B | +11.8% | $2.56 |
| Q2 FY2026 | 30 Jun 2026 | $3.33B | +12.5% | $4.31 |
| Q1 FY2026 | 31 Mar 2026 | $2.99B | +7.8% | $4.02 |
| Q4 FY2025 | 31 Dec 2025 | $3.19B | +9.5% | $4.65 |
| Q3 FY2025 | 30 Sep 2025 | $3.08B | +11.0% | $4.20 |
| Q2 FY2025 | 30 Jun 2025 | $2.96B | +12.1% | $3.99 |
| Q1 FY2025 | 31 Mar 2025 | $2.77B | +3.0% | $2.49 |
| Q4 FY2024 | 31 Dec 2024 | $2.91B | +15.7% | $3.55 |
More on Vertex Pharmaceuticals: financial statements · revenue · earnings per share
VRTX's results, as they are filed.
Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.
